AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 9.8 |
Market Cap | 985.91M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -5.45 |
PE Ratio (ttm) | -1.78 |
Forward PE | n/a |
Analyst | Buy |
Ask | 9.94 |
Volume | 2,605,903 |
Avg. Volume (20D) | 2,823,255 |
Open | 10.11 |
Previous Close | 10.05 |
Day's Range | 9.59 - 10.39 |
52-Week Range | 9.59 - 34.87 |
Beta | undefined |
About NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline...
Analyst Forecast
According to 17 analyst ratings, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $54, which is an increase of 457.85% from the latest price.
Next Earnings Release
Analysts project revenue of $8.90M, reflecting a -564.27% YoY shrinking and earnings per share of -1.33, making a -8.90% decrease YoY.
2 months ago · seekingalpha.com
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In FocusIntellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month'...
2 months ago · seekingalpha.com
Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call TranscriptIntellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Lina Li - Senior Director of Investor Relations and Corporate Communication...
2 months ago · seekingalpha.com
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying OpportunityIntellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week pri...
2 months ago · schaeffersresearch.com
2 Biotech Stocks Making Big MovesThe ever-volatile biotech sector is making noise today.